Jul 18, 2020 · 0066 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) Therapy - Diabetes or Left Ventricular Systolic …

The National Quality Forum (NQF) improves the quality of American healthcare by setting national priorities for performance improvement, endorsing consensus standards for measuring and …

Sep 23, 2020 · Welcome, Introductions, and Review of Meeting Objectives NQF welcomed the Standing Committee and participants to the web meeting. NQF staff reviewed the meeting …

Jun 12, 2020 · The recommended measures are: NQF 0066 Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) …

The four measures recommended by the Standing Committee are: 0066: Coronary Artery Disease (CAD): Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker …

#0066: CAD: ACE inhibitor/angiotensin receptor blocker (ARB) Therapy American Medical Association-Physician Consortium for Performance Improvement of patients with CAD who …

The measure estimates a hospital-level risk-standardized readmission rate (RSRR) of unplanned, all-cause readmission after admission for any eligible condition within 30 days of hospital …

0066: Chronic Stable Coronary Artery Disease: ACE Inhibitor or ARB Therapy--Diabetes or Left Ventricular Systolic Dysfunction (LVEF <40%) 0018: Controlling High Blood Pressure 1529: …

Cardiovascular Measure Evaluation Recusals The NQF CDP Conflict of Interest Policy requires that Committee members identified as having a potential conflict of interest in relation to …

Oct 7, 2016 · Background In Phase 4 of this project, the 24-member Cardiovascular Standing Committee met during a 1-day in-person meeting to evaluate a total of six measures against …